Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. has a positive outlook primarily due to its innovative approach with ficerafusp alfa, a bifunctional antibody that targets key pathways in cancer treatment, notably in head and neck squamous cell carcinoma (HNSCC) where the probability of success has been raised to 65%. The company’s strategy to capture substantial market share in HNSCC, expected to reach 35% in the event of regulatory approval, underscores the potential commercial success that could arise from their promising clinical results. Furthermore, Bicara's ongoing investigations into ficerafusp alfa's efficacy in combination therapies may yield significant advancements in treatment options, with expectations for critical clinical updates by 2026 that could further enhance market confidence.

Bears say

Bicara Therapeutics Inc. faces a negative outlook due to several fundamental concerns surrounding its lead program, ficerafusp alfa, which is projected to deliver underwhelming clinical results, ultimately reducing the probability of success in head and neck squamous cell carcinoma (HNSCC) to 30%. The projected net loss of $2.56 per share for full-year 2026 highlights the company's ongoing financial challenges, exacerbated by the risk of insufficient efficacy or safety issues that could hinder further development. Additionally, a lack of differentiated clinical data along with the competitive landscape may limit ficerafusp alfa's commercial potential, posing significant risks to its sales and market uptake.

BCAX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 9 analysts, BCAX has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.